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Summary 
The prediction interval has been increasingly used in meta-analyses as a useful measure 
for assessing the magnitude of treatment effect and between-studies heterogeneity. In 
calculations of the prediction interval, although the Higgins–Thompson–Spiegelhalter 
method is used most often in practice, it might not have adequate coverage probability 
for the true treatment effect of a future study under realistic situations. An effective 
alternative candidate is the Bayesian prediction interval, which has also been widely used 
in general prediction problems. However, these prediction intervals are constructed based 
on the Bayesian philosophy, and their frequentist validities are only justified by large-
sample approximations even if non-informative priors are adopted. There has been no 
certain evidence that evaluated their frequentist performances under realistic situations of 
meta-analyses. In this study, we conducted extensive simulation studies to assess the 
frequentist coverage performances of Bayesian prediction intervals with 11 non-
informative prior distributions under general meta-analysis settings. Through these 
simulation studies, we found that frequentist coverage performances strongly depended 
on what prior distributions were adopted. In addition, when the number of studies was 
smaller than 10, there were no prior distributions that retained accurate frequentist 
coverage properties. We also illustrated these methods via applications to eight real meta-
analysis datasets. The resultant prediction intervals also differed according to the adopted 
prior distributions. Inaccurate prediction intervals may provide invalid evidence and 
misleading conclusions. Thus, if frequentist accuracy is required, Bayesian prediction 
intervals should be used cautiously in practice. 
 
Key words: meta-analysis; heterogeneity; random-effects model; prediction intervals; 
Bayesian prediction 
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1. Introduction 
Random-effects models have been the primary statistical tools for meta-analyses since 
they enable quantitative evaluation of the average treatment effects accounting for the 
between-studies heterogeneity 1,2. Conventionally, the “grand mean” parameter has been 
addressed as a primary estimand of these evidence synthesis studies, but its ability to 
express a summarized measure of treatment effects among multiple studies is 
substantially limited because it is solely a point measure that corresponds to the mean of 
the random-effects distribution. To quantify the true effect and effectiveness in real-world 
uses of the treatment, more appropriate measures are required that suitably reflect the 
degree of heterogeneity and magnitude of the treatment effect. The prediction interval 
was proposed to address this problem; it is defined as an interval that covers the true 
treatment effect in a future study with certain probability 3,4. 
The prediction interval has been gaining prominence in recent meta-analyses 
because it enables the simultaneous assessment of uncertainties in treatment effects and 
heterogeneity between studies 5,6. The Higgins–Thompson–Spiegelhalter (HTS) method 
3 has been most widely used for calculation of the prediction interval. The HTS method 
is computational efficient and practically useful, but in a recent study by Partlett and Riley 
7, the HTS prediction interval can have poor coverage properties when the number of 
studies 𝑛 is small. The most important reason for this is that HTS method is based on 
the large-sample approximation in which 𝑛  is sufficiently large. In medical meta-
analyses, 𝑛 is usually less than 20 8; therefore, the large-sample approximation can be 
violated, similar to the problem with inference of the grand mean 9-11.  
An effective alternative approach is Bayesian prediction methods, which have 
been extensively investigated for general statistical prediction problems 12,13. Higgins et 
al. 3 also discussed Bayesian approaches in the context of constructing the prediction 
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interval for meta-analyses. Although the Bayesian approach is always “exact” if it is used 
as a purely subjective method, most cases adopt non-informative prior distributions and 
use as objective Bayesian approaches 14,15. When using non-informative prior 
distributions, the resultant predictions (inferences) are good approximations of frequentist 
predictions (inferences) 12,13,16; accordingly, these methods have often been used in 
practice as if they were frequentist methods. However, a Bayesian prediction interval is 
rigorously defined as an interval within which a future value falls with a particular 
subjective probability, and its concordance with the frequentist probability is only assured 
under large-sample settings 12. In practical situations of meta-analyses in medical research, 
𝑛 is limited (usually < 20) 8. Also, several simulation-based studies have indicated that 
Bayesian inferences are not necessarily accurate in the frequentist sense 17, and their 
frequentist performances vary dramatically among prior distributions 18. To date, there is 
no definitive evidence regarding how Bayesian prediction intervals perform in practical 
meta-analysis situations.  
In this article, we conducted extensive simulation studies to assess the frequentist 
coverage performances of the Bayesian prediction intervals with various 11 non-
informative priors. In addition, we provide eight illustrative examples of analyses selected 
from recently published systematic reviews in leading medical journals (BMJ, Lancet, 
and JAMA). Our aim was to obtain certain numerical evidence for the operating 
characteristics of Bayesian prediction methods, as well as to provide recommendations 
for the practical use of these methods. We also provide related simulation and real data 
analysis results for the credible intervals in the Supporting Information. 
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2. Prediction intervals for meta-analysis 
We consider that there are 𝑛  clinical trials and 𝑦௜ ሺ𝑖 ൌ 1,2, … , 𝑛ሻ  is the estimated 
treatment effect measure in the 𝑖 th trial. Commonly used effect measures are mean 
difference, standardized mean difference, risk difference, risk ratio, and odds ratio 19,20; 
the ratio measures are typically transformed to logarithmic scales. The random-effects 
model in meta-analyses 1,2 is then defined as 
𝑦௜~𝑁ሺ𝜃௜, 𝜎௜ଶሻ       (1) 
𝜃௜~𝑁ሺ𝜇, 𝜏ଶሻ 
where 𝜃௜ is the true effect size of the 𝑖th study, and 𝜇 is the grand mean parameter. 𝜎௜ଶ 
and 𝜏ଶ  express within- and across-studies variances; 𝜎௜ଶ  is usually assumed to be 
known and fixed to their valid estimates. The across-studies variance 𝜏ଶ represents the 
degree of heterogeneity across studies. Conventionally, the grand mean parameter 𝜇 is 
used as a summary measure of the random-effects meta-analysis as an average treatment 
effect, and it is estimated as ?̂? ൌ ሺ∑ 𝑤ෝ௜௡௜ୀଵ 𝑦௜ሻ ሺ∑ 𝑤ෝ௜௡௜ୀଵ ሻ⁄ , where 𝑤ෝ௜ ൌ ሺ𝜎௜ଶ ൅ ?̂?ଶሻିଵ; ?̂?ଶ 
is an estimator of the heterogeneity variance, e.g., the method of moment estimator 
proposed by DerSimonian and Laird 1. However, when certain heterogeneity exists, the 
point measure has a limited ability to utilize meta-analysis evidence for medical policy 
making and health technology assessments; its effectiveness should be evaluated 
considering the heterogeneity in the target population. Thus, the prediction interval has 
been gaining prominence as a way to add useful information involving the uncertainty of 
the treatment effect and its heterogeneity 5,6. 
The 100ሺ1 െ 𝛼ሻ% prediction interval in meta-analysis is formally defined as 
an interval that covers the treatment effect 𝜃௡௘௪ in a future study with 100ሺ1 െ 𝛼ሻ% 
probability 3,4. Higgins et al. 3 proposed a simple plug-in type prediction interval, 
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ቈ?̂? െ 𝑡௡ିଶఈ ට?̂?஽௅ଶ ൅ 𝑉𝑎𝑟෢ ሾ?̂?ሿ, ?̂? ൅ 𝑡௡ିଶఈ ට?̂?஽௅ଶ ൅ 𝑉𝑎𝑟෢ ሾ?̂?ሿ቉ 
where ?̂?஽௅ଶ  is the DerSimonian-Laird’s method-of-moment estimator 1 of 𝜏ଶ, 𝑉𝑎𝑟෢ ሾ?̂?ሿ ൌ
1 ሺ∑ ሺ𝜎௜ଶ ൅ ?̂?஽௅ଶ ሻିଵ௡௜ୀଵ ሻ⁄  is the variance estimator of ?̂?, and 𝑡௡ିଶఈ  is the 100ሺ1 െ 𝛼 2⁄ ሻ 
percentile of the t-distribution with 𝑛 െ 2  degrees of freedom. The HTS prediction 
interval is based on two approximations: ሺ?̂? െ 𝜇ሻ ඥ𝑉𝑎𝑟෢ ሾ?̂?ሿ⁄   is approximately 
distributed as N(0, 1), and ሺ𝑛 െ 2ሻሺ?̂?஽௅ଶ ൅ 𝑉𝑎𝑟෢ ሾ?̂?ሿሻ ሺ𝜏ଶ ൅ 𝑉𝑎𝑟෢ ሾ?̂?ሿሻ⁄   is approximately 
distributed as χଶሺ𝑛 െ 2ሻ. These approximations are generally not accurate under small- 
or moderate-𝑛  settings. Thus, in the simulation studies of Partlett and Riley 7 and 
Nagashima et al. 21, the coverage probability of the prediction interval for 𝜃௡௘௪ was 
below the nominal level under general settings of meta-analyses of medical studies, 
especially when 𝑛 ൏ 20 8. To address the undercoverage problems, Partlett and Riley 7 
proposed other plug-in–type intervals instead of ?̂?஽௅ଶ  , e.g., the restricted maximum 
likelihood (REML) estimator or the Hartung–Knapp estimator 22. Also, Nagashima et al. 
21 proposed a parametric bootstrap–based approach using a confidence distribution. In 
their extensive simulation studies, Nagashima et al. 21 showed that the coverage 
probability of their prediction interval accorded to the nominal level consistently. These 
prediction intervals are all calculable using the pimeta package 23 in R (R Foundation 
for Statistical Computing, Vienna, Austria).  
 
3. Bayesian prediction intervals 
3.1 The Bayesian hierarchical model and prediction 
The Bayesian framework using the Markov Chain Monte Carlo (MCMC) is an 
established prediction method in statistics, and represents an alternative effective 
approach for the prediction problem. Higgins et al. 3 also discussed the uses of the 
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Bayesian methods in addressing the prediction problem in meta-analyses. In the Bayesian 
framework, a prediction distribution for the effect 𝜃௡௘௪ is computable by sampling a 
new study, 𝜃௡௘௪~𝑁ሺ𝜇, 𝜏ଶሻ 3,24 by MCMC. A 95% prediction interval for the new study 
is obtained simply from the 2.5% and 97.5% quantiles of the posterior distribution of 
𝜃௡௘௪.  
A Bayesian hierarchical model for the random-effects model (1) is ordinarily 
constructed assuming prior distributions for the parameters of random-effects distribution 
𝜇 and 𝜏ଶ. The purely Bayesian predictions can be conducted under this framework, but 
here we consider using this Bayesian framework to conduct approximate frequentist 
predictions using non-informative priors, i.e., to provide an accurate prediction interval 
with a sense of frequentist probability.  
 
3.2 Prior distributions for approximate frequentist prediction 
Various non-informative prior distributions are considered for the meta-analysis model 18. 
Lambert et al. 18 also conducted large simulation studies to assess the frequentist 
performances of the inferences of 𝜇 and 𝜏ଶ, and concluded that they strongly depended 
on the prior distribution of 𝜏ଶ . Following their discussions, we considered 11 non-
informative priors involving improper priors to assess the impact on prediction accuracy, 
which is involved in the recently developed bayesmeta package in Röver 15, which 
uses various modern methods to select a prior distribution. For the grand mean parameter 
𝜇, we consistently used a diffuse Gaussian distribution, 
𝜇~𝑁ሺ0,10000ሻ 
Also, we considered the standard factorable prior distribution, which can be factored into 
independent marginal, 𝑝ሺ𝜇, 𝜏ሻ ൌ 𝑝ሺ𝜇ሻ ൈ 𝑝ሺ𝜏ሻ . The 11 prior distributions for 𝜏ଶ 
considered here were as follows. 
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3.2.1 Uniform prior distributions for 𝜏 
𝑝ሺ𝜏ሻ ∝ 1 
This prior distribution is the most intuitive flat non-informative improper prior for the 
heterogeneity standard deviation parameter 𝜏 15. In addition, as a popular choice in these 
Bayesian analyses, a proper uniform prior on a limited range can be also considered. One 
choice would be 𝜏~Uniformሺ0,10ሻ, which is a flat uniform distribution on (0, 10).  
 
3.2.2 Uniform prior distribution in √𝜏 
𝑝ሺ𝜏ሻ ∝ 1√𝜏 
This is the uniform prior in √𝜏. It has been proposed that a requirement is reasonable for 
non-informative priors, because it has invariance with respect to re-scaling of 𝜏 25,26. 
Due to this requirement, a family of improper prior distribution with density is 𝑝ሺ𝜏ሻ ∝
𝜏௔ (െ∞ ൏ 𝑎 ൏ ∞). As a special case, this prior distribution corresponds to 𝑎 ൌ െ0.50 
expressing a monotonically decreasing density function; 𝑎 ൌ 0  corresponds to the 
improper uniform prior in Section 3.2.1. 
 
3.2.3 Jeffreys prior distribution 
𝑝ሺ𝜏ሻ ∝ ඩ෍ ቆ 𝜏𝜎௜ଶ ൅ 𝜏ଶቇ
ଶ௡
௜ୀଵ
 
This is the non-informative Jeffreys prior 27, which is formally given by 𝑝ሺ𝜇, 𝜏ሻ ∝
ඥdet ሺ𝐽ሺ𝜇, 𝜏ሻሻ where 𝐽ሺ𝜇, 𝜏ሻ is the Fisher information matrix. In the present Bayesian 
hierarchical model, the two parameters 𝜇 and 𝜏ଶ are orthogonal in the sense that the 
off-diagonal elements of the Fisher information matrix are 0, and the Jeffreys prior 
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corresponds to the Tibshirani’s non-informative prior 28; then, the prior density function 
is given above. This prior also corresponds to the Berger–Bernardo reference prior 14,29. 
 
3.2.4 Berger–Deely prior distribution 
𝑝ሺ𝜏ሻ ∝ ෑ ቆ 𝜏𝜎௜ଶ ൅  𝜏ଶቇ
ଵ/௡௡
௜ୀଵ
 
This is another variation of the Jeffreys prior, provided by Berger and Deely 30. This prior 
distribution is also improper, and is concordant with the Jeffreys prior when all within-
study variances 𝜎௜ଶ are equal. 
 
3.2.5 The proper conventional prior distribution 
𝑝ሺ𝜏ሻ ∝ ෑ ቆ 𝜏ሺ𝜎௜ଶ ൅  𝜏ଶሻଷ/ଶቇ
ଵ/௡௡
௜ୀଵ
 
This is a proper variation of the Jeffreys prior that was proposed by Berger and Deely 30. 
This prior distribution is intended as a non-informative, but is used as a proper one for 
testing or model selection purposes 30 31. 
 
3.2.6 DuMouchel prior distribution 
𝑝ሺ𝜏ሻ ൌ 𝑠଴ሺ𝑠଴ ൅ 𝜏ሻଶ ,  𝑠଴
ଶ ൌ 𝑛∑ 𝜎௜ି ଶ௡௜ୀଵ  
This is the DuMouchel prior distribution 16,32 for the heterogeneity parameter 𝜏. 𝑠଴ଶ is 
the harmonic mean of within-study variances 𝜎௜ଶ. This prior corresponds to a log-logistic 
distribution for 𝜏 that has the mode at 0 and the median at 𝑠଴. 
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3.2.7 Uniform shrinkage prior distribution 
𝑝ሺ𝜏ሻ ൌ 2𝑠଴
ଶ𝜏
ሺ𝑠଴ଶ ൅ 𝜏ଶሻଶ ,  𝑠଴
ଶ ൌ 𝑛∑ 𝜎௜ି ଶ௡௜ୀଵ  
This prior distribution is derived as a uniform prior for the average shrinkage factor 
𝑆଴ሺ𝜏ሻ ൌ 𝑠଴ଶ ሺ𝑠଴ଶ ൅ 𝜏ଶሻ⁄  16,33. The median is also 𝑠଴ , and the forms of the DuMouchel 
prior and this prior depend on the harmonic mean 𝑠଴. The uniform prior for 𝑆଴ሺ𝜏ሻ is 
equivalent to a uniform prior of 1 െ 𝑆଴ሺ𝜏ሻ ൌ 𝜏ଶ ሺ𝑠଴ଶ ൅ 𝜏ଶሻ⁄ , which has similar form to 
the Higgins’ I2 statistic 34. 
 
3.2.8 Uniform prior distribution in 𝐼ଶ statistic 
𝑝ሺ𝜏ሻ ൌ 2𝜎ො
ଶ𝜏
ሺ𝜎ොଶ ൅ 𝜏ଶሻଶ ,  𝜎ො
ଶ ൌ ሺ𝑛 െ 1ሻ ∑ 𝜎௜ି
ଶ௡௜ୀଵ
ሺ∑ 𝜎௜ି ଶ௡௜ୀଵ ሻଶ െ  ∑ 𝜎௜ି ସ௡௜ୀଵ  
This is the uniform prior distribution for Higgins’ I2 statistic 34. As mentioned in Section 
3.2.7, this prior density is obtained by substituting the harmonic mean 𝑠଴ଶ for their 
average 𝜎ොଶ from the uniform shrinkage prior; these two priors have similar forms. 
 
3.2.9 Proper inverse-Gamma prior distributions 
1
𝜏ଶ ~Gammaሺ0.001, 0.001ሻ 
This prior distribution is the most commonly used semi-conjugate prior for the 
heterogeneity variance parameter 18. The shape of this prior distribution is mostly flat over 
a wide range, but has a small mode near 0. In addition, we considered a variation of this 
prior, 
1
𝜏ଶ ~Gammaሺ0.01, 0.01ሻ 
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whose two parameters were changed. This prior is also a vague prior for 𝜏ଶ, but more 
informative than the above prior. Using this prior, we can assess the sensitivity of altering 
the hyperparameters to the frequentist performance of the prediction interval. 
 
4. Simulations 
4.1 Designs and settings 
We conducted a series of simulation studies to provide certain evidence for frequentist 
performances of Bayesian prediction intervals for meta-analyses. We adopted 11 priors 
for 𝜏ଶ explained in Section 3, (1) the uniform improper prior in 𝜏 (Uniform), (2) the 
uniform improper prior in √𝜏 (Sqrt), (3) the Jeffreys prior (Jeffreys), (4) the Berger–
Deely prior (Berger–Deely), (5) the proper conventional prior (Conventional), (6) the 
DuMouchel prior (DuMouchel), (7) the uniform shrinkage prior (Shrinkage), (8) the 
uniform prior for I2 statistic (I2) , (9) the proper uniform prior U(0, 10) (Proper 1), (10) 
the proper inverse-Gamma prior Gammaሺ0.001, 0.001ሻ  (Proper 2), and (11) the 
inverse-Gamma prior Gammaሺ0.01, 0.01ሻ (Proper 3). The 95% prediction intervals for 
a future study were calculated based on the 2.5% and 97.5% quantiles of the posterior 
distribution of 𝜃௡௘௪~𝑁ሺ𝜇, 𝜏ଶሻ . We used the bayesmeta package 15 in R and 
OpenBUGS 35 for computations. Also, we added the HTS interval (HTS) as a reference 
method. 
The simulation data were generated mimicking the simulation settings of 
Brockwell and Gordon 9,36, which consider typical settings of meta-analyses in medical 
studies that assess an overall odds-ratio. The grand mean parameter 𝜇 was set to 0, 
without loss of generality for assessing coverage and precision of the prediction intervals. 
The within-study variances 𝜎௜ଶ were generated from a chi-squared distribution with 1 
degree of freedom, multiplied by 0.25, and truncated within an interval [0.009, 0.6]. The 
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number of studies 𝑛 and the heterogeneity variance 𝜏ଶ were varied for two patterns: 
(1) 𝑛 was fixed to 7 or 15, and 𝜏ଶ varied among 0.01, 0.02,…,0.20, and (2) 𝜏ଶ was 
fixed to 0.10 or 0.20, and 𝑛 varied among 4, 5, 6,…,20. For each scenario, we simulated 
10000 replications. We assessed the empirical covariate rates of randomly generated 
𝜃௡௘௪~𝑁ሺ𝜇, 𝜏ଶሻ of the 12 prediction intervals and their empirical expected widths for the 
10000 results. The coverage probabilities are desirable to accord the nominal level, 95%. 
We also assessed the coverage performances of credible intervals for the 11 priors. The 
results are presented in e-Appendix A in Supporting Information. 
 
4.2 Results 
First, the results of the simulation studies for the scenarios in which 𝑛 was fixed and 𝜏ଶ 
was varied are presented in Figure 1. Under both settings for the number of studies (𝑛 ൌ
7, 15ሻ settings, most of the Bayesian methods exhibited overcoverage when 𝜏ଶ ൌ 0.01; 
only HTS had coverage probabilities around 0.95. However, when 𝜏ଶ grew larger, HTS 
exhibited undercoverage. HTS consistently exhibited undercoverage when 𝜏ଶ ൐ 0.01, 
and these results were consistent with previous simulation studies 7,21. Under 𝑛 ൌ 7, the 
coverage probabilities for Sqrt, DuMouchel, and Proper 2 were below the nominal level 
when there was certain heterogeneity. Under 𝑛 ൌ 15, they also exhibited undercoverage 
under smaller 𝜏ଶ. However, their coverage probabilities were generally larger when 𝜏ଶ 
grew larger. The simulation results of Shrinkage and I2 had similar trends because of the 
similarities in the shapes of their prior distributions. These two methods also exhibited 
overcoverage when 𝜏ଶ ൏ 0.05; but as heterogeneity got larger, they tended to exhibit 
undercoverage. For Uniform, Jeffreys, Berger–Deely, Conventional, Proper 1, and Proper 
3, the coverage probabilities were above the nominal level regardless of the degree of 
heterogeneity under 𝑛 ൌ 7; when 𝜏ଶ ൌ 0.20, the coverage probabilities of Conventional 
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and Proper 3 were around 0.95. Also, their expected widths were larger than those of the 
aforementioned priors. Under 𝑛 ൌ 15 , they exhibited overcoverage when 𝜏ଶ ൏ 0.10 , 
and had accurate coverage probability around the nominal level when 𝜏ଶ ൒ 0.10, except 
for Proper 3. Proper 3 exhibited undercoverage when 𝜏ଶ ൒ 0.10 ; also, only Berger–
Deely tended to exhibit overcoverage. The results of Proper 2 and Proper 3 were quite 
different, although they were the same parametric inverse-gamma priors; the differences 
indicate sensitivity to the selection of hyperparameters, and suggest that these trends 
might change if the simulation settings are altered. These results reveal that we cannot 
explicitly specify which priors can provide accurate prediction intervals in general. The 
expected widths clearly reflected the trends of coverage probabilities. From the above, 
Uniform, Jeffreys, Berger–Deely, Conventional, Proper 1 had accurate frequentist 
coverage properties when 𝑛 ൌ 15, 𝜏ଶ ൒ 0.10 . However, the others exhibited 
undercoverage or overcoverage, and did not provide accurate prediction intervals in the 
frequentist sense. 
Second, the results of simulation studies for the scenarios in which 𝜏ଶ was fixed 
and 𝑛 was varied are presented in Figures 2. Under 𝜏ଶ ൌ 0.10, when the number of 
studies were extremely small (𝑛 ൌ 4,5ሻ, DuMouchel, Shrinkage, I2, Proper 2, and HTS 
had the most accurate coverage probabilities. However, as 𝑛  got larger, these five 
methods exhibited undercoverage. In particular, the coverage probabilities of DuMouchel 
were below 0.90. For Sqrt, the coverage probabilities were above the nominal level when 
𝑛 ൑ 6, but far below 0.95 when 𝑛 ൐ 6. Uniform, Jeffreys, Berger–Deely, Conventional, 
Proper 1, and Proper 3 tended to exhibit overcoverage when 𝑛 ൏ 12; when 𝑛 ൒ 12, they 
had accurate coverage probabilities except for Proper 3, which exhibited undercoverage 
then. Among these priors, Berger–Deely exhibited the greatest degree of overcoverage. 
Under 𝜏ଶ ൌ 0.20, DuMouchel, Shrinkage, I2, Proper 2 and HTS consistently exhibited 
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undercoverage, but when 𝑛  grew larger, their coverage performances improved. In 
addition, the coverage probabilities of Sqrt and Conventional were above the nominal 
level under 𝑛 ൑ 5 or 6, but they tended to exhibit undercoverage when 𝑛 ൐ 6, with 
Sqrt exhibiting undercoverage to a greater degree. Uniform, Jeffreys, Berger–Deely, 
Proper 1 exhibited overcoverage under 𝑛 ൑ 10, but they had generally accurate coverage 
probabilities when 𝑛 ൐ 10. Proper 3 exhibited overcoverage when 𝑛 ൑ 6, but exhibited 
undercoverage when 𝑛  grew larger. In addition, under these settings, the coverage 
performances of Proper 2 and Proper 3 were also quite different. When 𝑛 grew larger, 
the differences got to be smaller, because the relative information of observed data got 
larger. The expected widths also clearly reflected the trends in coverage probabilities; 
Uniform and Proper 1 had markedly larger expected widths than the other priors when 
𝑛 ൌ 4 or 5. Overall, Uniform, Jeffreys, Berger–Deely, Proper 1 had accurate frequentist 
coverage properties when 𝜏ଶ ൌ 0.10, 𝑛 ൒ 12  and 𝜏ଶ ൌ 0.20, 𝑛 ൒ 11 ; Conventional 
also achieved nearly accurate coverage performance. However, the others exhibited 
undercoverage or overcoverage, and did not provide accurate prediction intervals in the 
frequentist sense. Therefore, there are not favourable prediction intervals, especially 
under 𝑛 ൏ 10, that we can recommend as accurate prediction tools in frequentist sense 
in meta-analyses of medical studies. 
 
5. Real data examples 
For illustrative purposes, we applied Bayesian prediction intervals to eight real data 
examples that were recently published in leading medical journals (BMJ, Lancet and 
JAMA). The summary of eight datasets is presented in Table 1. To describe operational 
characteristics of various prediction intervals in details, we chose the example datasets 
with various characteristics: the numbers of studies were distributed among 3 to 22, and 
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their heterogeneity variance estimates were valued from 0.00 to 0.60. We present the 
Bayesian prediction intervals using the 11 reference priors adopted in Section 4. In 
addition, as reference methods, we also present the HTS interval (HTS), the HTS interval 
using the Hartung–Knapp variance estimator (HTS–HK), the HTS interval using the 
Sidik–Jonkman bias-corrected variance estimator (HTS–SJ) 7, and the prediction 
interval–based parametric bootstrap approach using the confidence distribution (pimeta) 
of Nagashima et al. 21 as reference methods.  
The results are presented in Figures 3 and 4. We also present the 95% credible 
intervals for the grand mean parameter 𝜇 for the eight meta-analyses. The results are 
presented in e-Appendix B in Supporting Information. 
 
5.1 CPR data 
Hüpfl et al. 37 conducted a meta-analysis to assess the association of chest-compression–
only cardiopulmonary resuscitation (CPR) with survival in patients who experience out-
of-hospital cardiac arrest. The outcome was survival to hospital discharge or 30-day 
survival, and the outcome measure was the risk ratio (RR). Figure 3 (a) presents the 95% 
prediction intervals for this dataset. This meta-analysis included three studies. The 
DerSimonian-Laird heterogeneity variance estimate was 0.00 . For this dataset, the 
Uniform and Proper 1 prediction intervals were the widest, and the widths were several 
times greater than the narrowest (DuMouchel and Shrinkage). These results were 
consistent with simulation results in which the expected widths of Uniform and Proper 1 
were especially large when 𝑛 was small. Also, the widths of the prediction intervals were 
quite different among different prior distributions. Berger–Deely, Jeffreys, Sqrt, and 
Proper 3 also provided relatively wide prediction intervals. Compared with the pimeta 
and HTS methods, these results might lead to different interpretations. However, all 
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prediction intervals included 1, potentially indicating that there were some 
subpopulations in which the treatment effect was null or harmful; although the overall 
RR was 1.215 (95%CI: 1.009, 1.464). 
 
5.2 Corticosteroids data 
This meta-analysis was conducted to estimate the benefits and harms of using 
corticosteroids as an adjunct treatment for sore throat 38. The outcome was complete 
resolution of pain and the effect measure was RR. Figure 3 (b) presents the 95% prediction 
intervals of this dataset. The data included five studies and indicated a certain 
heterogeneity (?̂?஽௅ଶ ൌ 0.33, 𝑝 ൌ 0.014). The Uniform and Proper 1 intervals were also the 
widest among the comparators. Besides, the Shrinkage and I2 intervals were the 
narrowest. Among the frequentist methods, the HTS, HTS–HK, HTS–SJ, and pimeta 
intervals were not so different. All prediction intervals were quite wide and included 1, 
and they might indicate there are some subpopulations for which the treatment effect is 
null or harmful; although the overall RR was 2.233 (95% CI: 1.177, 4.235). 
 
5.3 QOL data 
Gaertner et al. 39 conducted a meta-analysis to assess the effect of specialist palliative care 
on quality of life (QOL). The outcome measures were different among the seven studies 
(e.g., European Organization for Research and Treatment of Cancer quality of life 
questionnaire; EORTC QLQ-C30), and were synthesized as standardized mean difference 
(SMD). Figure 3 (c) presents the 95% prediction intervals of this dataset. The 
heterogeneity variance estimate was the largest among the eight examples ( ?̂?஽௅ଶ ൌ
0.60, 𝑝 ൏ 0.001). The Uniform and Proper 1 intervals were also the widest, as in the 
former two examples. The I2 and Shrinkage intervals were the narrowest among the 
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Bayesian prediction intervals, and HTS was the narrowest among all comparators. Also, 
the Berger–Deely interval was concordant with the Jeffreys interval, because the within-
study variances for individual studies were equal. For this dataset, the overall SMD was 
0.569 (−0.017, 1.154) and was not significant. Also, all prediction intervals included 0, 
suggesting that there were some subpopulations in which the treatment effect was null or 
harmful. 
 
5.4 PPI data 
Crocker et al. 40 investigated the impact of patient and public involvement (PPI) on rates 
of enrolment and retention by a systematic review of clinical trials. The outcome was 
patient enrolment rate, and the outcome measure was odds ratio (OR). Figure 3 (d) 
presents the 95% prediction intervals of this data. The data included eight studies and 
indicated small heterogeneity (?̂?஽௅ଶ ൌ 0.00). The Berger–Deely interval was the widest 
for this dataset, and Conventional, Jeffreys, Uniform, Proper 1, and Proper 3 intervals 
were comparable with it. Although all the 11 Bayesian prediction intervals and pimeta 
interval included 1, the HTS, HTS–HK and HTS–SJ intervals did not. The HTS intervals 
indicated certain heterogeneity, but implied that the directions of OR are consistent in the 
target population. Besides, the other Bayesian prediction and pimeta methods indicated 
that the directions might change for certain subpopulations. The interpretations and 
conclusions of this meta-analysis might change among the different prediction methods. 
 
5.5 SBP data 
This dataset was provided as a hypothetical meta-analysis analysed in Riley et al. 4. They 
generated a hypothetical dataset examining an effect of an antihypertensive drug. The 
outcome was systolic blood pressure (SBP; mmHg), and the outcome measure was SMD. 
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The dataset included 10 studies and exhibited moderate heterogeneity (?̂?஽௅ଶ ൌ 0.03, 𝑝 ൏
0.001). Figure 4 (e) presents the 95% prediction intervals. The Uniform and Proper 1 
intervals were the widest, and the Shrinkage interval the narrowest, in terms of Bayesian 
prediction intervals. The HTS–HK and HTS–SJ intervals were markedly wider than the 
HTS interval, because the heterogeneity variance estimate by DerSimonian–Laird’s 
method was smaller than that of the REML method. Although there was some difference 
in prediction intervals, all prediction intervals included 0; the overall SMD was −0.334 
(95%CI: −0.484, −0.184). 
 
5.6 DPP-4 data 
This meta-analysis was conducted to quantify the risk of hypoglycaemia with dipeptidyl 
peptidase-4 (DPP-4) inhibitors and sulphonylureas compared with placebo and 
sulphonylureas 41. The outcome was an incidence of hypoglycaemia, and the effect 
measure was RR. Figure 4 (f) presents the prediction intervals of this data. The data 
included 10 studies and revealed moderate heterogeneity (𝜏஽௅ଶ ൌ 0.02 ). The Berger–
Deely, Conventional, Jeffreys, Uniform, Proper 1 and Proper 3 intervals were wider than 
the others. Also, HTS–HK and HTS–SJ were narrower than the HTS interval. Although 
the overall RR was 1.513 (95%CI: 1.219, 1.878), these prediction intervals might lead 
different interpretations of the results. The HTS–HK and HTS–SJ intervals did not 
include 1, and the Bayesian, HTS and pimeta intervals involved 1.  
  
5.7 Breakfast data 
Sievert et al. 42 examined the effect of regular breakfast consumption on weight change. 
The outcome was weight change (kg), and the outcome measure was mean difference 
(MD). Figure 4 (g) presents the 95% prediction intervals. This meta-analysis included 10 
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studies, and the heterogeneity variance estimate was 0.13. The Berger–Deely, Uniform, 
and Proper 1 intervals were wider than the others, and the DuMouchel interval was the 
narrowest. This trend was consistent with the simulation results in the conditions 𝑛 ൌ 10 
and 𝜏ଶ ൌ 0.1 in Figure 2. There was a minimal difference in the prediction intervals, 
and all prediction intervals included 0. The HTS, HTS–HK, and HTS–SJ intervals were 
nearly equal, and slightly narrower than the pimeta interval. Although the grand mean 
was significantly larger than 0 (overall MD: 0.440, 95%CI: 0.065, 0.816), the direction 
of the effect might be changed for certain subpopulations. 
 
5.8 Pain data 
Häuser et al. 43 conducted a systematic review to compare the treatment effect of 
antidepressants on pain in patients with fibromyalgia syndrome. The outcomes were the 
pain questionnaire scores by VAS (visual analog scale), VASFIQ (visual analog scale 
fibromyalgia impact questionnaire) and NRS (numeric rating scale), and were 
synthesized as SMD. Figure 4 (h) presents the prediction intervals. The data included 22 
studies, and the heterogeneity variance estimate was 0.03 (p=0.012). Among the Bayesian 
prediction intervals, the Berger–Deely, Conventional, Jeffreys, Uniform, Proper 1 and 
Proper 3 intervals included 0; on the other hand, the DuMouchel, I2, Shrinkage, Sqrt, and 
Proper 2 intervals did not. As for the frequentist methods, the HTS, HTS–HK, and HTS–
SJ intervals did not include 0, but the pimeta interval did. Although the grand mean was 
significantly smaller than 0 (overall SMD: −0.427, 95%CI: −0.553, −0.302), the effect 
might be null for certain subpopulations. However, the interpretations and conclusions 
might differ based on the priors we adopted for this meta-analysis. 
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6. Discussion 
The prediction interval has been gaining prominence in recent meta-analyses, and could 
become a standard statistical output in meta-analyses in the near future because of its 
effectiveness for the assessment of heterogeneity and uncertainties of treatment effects in 
target populations 3-6. Bayesian prediction methods represent a useful approach in 
practices, but our study revealed that Bayesian prediction intervals are not necessarily 
accurate in the frequentist sense under practical situations.  
Especially, when the number of studies 𝑛 is smaller than 10, our simulation 
studies showed that the Bayesian prediction intervals based on all 11 reference priors did 
not have favorable coverage performances. Also, the coverage performances were quite 
different. Thus, we must choose the prior distributions carefully. In particular, some priors 
exhibited serious undercoverage properties (Sqrt, DuMouchel, Shrinkage, I2, Proper 2, 
and Proper 3), and might under-estimate the heterogeneity and uncertainty in practice. 
Besides, Uniform, Jeffreys, Berger–Deely, Conventional, Proper 1 exhibited good 
coverage performances, in particular when 𝑛 ൐ 10 ; however, they tended to provide 
overly wide prediction intervals when 𝑛 ൑ 10, and might yield vague evidence. 
If prediction intervals are too vague or too narrow, they can directly influence 
the conclusions of systematic reviews, providing misleading evidence for health 
technology assessments and policy making. Therefore, Bayesian prediction intervals 
should be carefully used in practice, and if there exist other accurate alternatives, they 
should be recommended. Certainly, it is not problematic if researchers wish to conduct 
purely Bayesian prediction with subjective probability, but most Bayesian applications in 
meta-analyses are conducted as objective Bayesian frameworks 15,18. 
Similar discussions have been provided in relation to the undercoverage problem 
of standard confidence intervals of grand mean parameter 𝜇 , and various improved 
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methods have been developed 9-11. Besides, for prediction intervals, rich methods do not 
yet exist. Currently, the confidence distribution approach of Nagashima et al. 21,23 
represents a suitable choice for accurate predictions; in their simulation-based numerical 
evaluations, they exhibited accurate coverage properties in general. In this regard, 
development of more rich methods for accurate predictions is needed, and represents an 
important priority for future work in research synthesis methodology. 
 
Data Availability Statement 
The meta-analysis datasets used in Section 5 are provided in the original papers 4,37-43. 
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Table 1 .Summary of the eight real data examples in Section 5 †. 
 
Dataset Reference Purpose Tested treatment (N) 
Control 
treatment (N) n Outcome 
Type of 
outcome 
variable 
Effect 
measure 
Overall estimate of μ 
 (95% CI) 𝜏஽௅ଶ  𝐼ଶ 
p-value  
of Q-
test 
CPR data Hüpfl M et al. 37 To assess the association of chest-compression-only cardiopulmonary resuscitation with survival in patients with 
out-of-hospital cardiac arrest 
Chest-compression-only 
cardiopulmonary 
resuscitation (1500) 
Standard 
cardiopulmonary 
resuscitation 
(1531) 
3 
Survival to 
hospital discharge  
or 30-day survival 
Binary RR 1.215 (1.009, 1.464) 0.00 0.0% 0.6845 
Corticosteroi
ds data 
Sadeghirad B et 
al. 38 To estimate the benefits and harms of using corticosteroids as an adjunct treatment for sore throat Corticosteroids (439) Placebo (424) 5 Complete resolution of pain Binary RR 2.233 (1.177, 4.235) 0.33 67.9% 0.0144 
QOL data Gaertner J et al. 39 To assess the effect of specialist palliative care on quality of life  Specialist palliative care (733) Standard care (652) 7 Quality of life Continuous SMD 0.569 (−0.017, 1.154) 0.60 96.2% <0.0001 
PPI data Crocker JC et al. 40 To investigate the impact of patient and public involvement on rates of enrolment and retention in clinical trials Patient and public involvement (9940) 
Non-patient and 
public involvement 
(8002) 
8 Patient enrolment rate Binary OR 1.165 (1.039, 1.306) 0.00 0.0% 0.4952 
SBP data Riley RD et al. 4 A hypothetical meta-analysis that assesses the blood pressure reduction effect of an 
antihypertensive drug 
- - 10 Systolic blood pressure (mmHg) 
Continuo
us SMD 
−0.334 (−0.484, 
−0.184) 0.03 70.5% 0.0004 
DPP-4 data Salvo S et al. 41 
To quantify the risk of hypoglycaemia 
associated with the concomitant use of 
dipeptidyl peptidase-4 inhibitors and 
sulphonylureas compared with placebo and 
sulphonylureas 
Dipeptidyl peptidase-4 
inhibitors and 
sulphonylureas (4020) 
Placebo and 
sulphonylureas 
(2526) 
10 Incidence of hypoglycaemia Binary RR 1.513 (1.219, 1.878) 0.02 19.0% 0.2680 
Breakfast 
data 
Sievert K et al. 
42 
To examine the effect of regular breakfast 
consumption on weight change Breakfast (213) 
Non-breakfast 
(216) 10 
Weight change 
(kg) 
Continuo
us MD 0.440 (0.065, 0.816) 0.13 42.9% 0.0722 
Pain data Häuser W et al. 43 To determine the efficacy of antidepressants in the treatment of Fibromyalgia syndrome Antidepressants (1153) Placebo (1143) 22 Pain questionnaire Continuous SMD −0.427 (−0.553, −0.302) 0.03 44.9% 0.0124 
 
† CI: confidence interval, RR: risk ratio, SMD: standardized mean difference, OR: odds ratio, MD: mean difference. 
 
  
 
 
 
 
 
  
 
Figure 1. Simulation results: coverage probabilities, and expected widths of the 95% prediction intervals. Varying 2 on 0.01, 0.02, 0.03,…, 0.20 under fixed n (=7, 15). 
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Figure 2. Simulation results: coverage probabilities and expected widths of the 95% prediction intervals. Varying n on 4, 5, 6,…, 20 under fixed 2 (=0.1, 0.2). 
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Figure 3. The 95% prediction intervals for four illustrative examples: (a) CPR data (n = 3), (b) corticosteroids data (n = 5), (c) QOL data (K = 7), and (d) PPI data (n = 8).  
 
 
 
  
 
Figure 4. The 95% prediction intervals for four illustrative examples: (e) SBP data (n = 10), (f) DPP-4 data (n = 10), (g) breakfast data (n = 10), and (h) pain data (n = 22).  
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e-Appendix A: Supplementary simulation results in Section 4 
In e-Figures 1 and 2, we provide supplementary simulation results for credible intervals 
that were obtained from the simulation studies described in Section 4. In these figures, 
we presented empirical coverage probabilities and expected widths of the 95% credible 
intervals of 𝜇 obtained from the 11 prior distributions. As a reference method, we also 
present those of the 95% DerSimonian-Laird (DL) confidence interval of 𝜇 
(DerSimonian and Laird, 1986). Similar simulation-based evidence for Bayesian 
inferences was also provided by Lambert et al. (2005). The simulation results presented 
here adopted different prior distributions and were obtained from different simulation 
settings; therefore, they provide useful numerical evidence for assessing the frequentist 
coverage performances of Bayesian inference methods in meta-analyses. The overall 
trends of the coverage properties and expected widths from the 11 priors were similar to 
those of the prediction intervals (Section 4). 
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e-Figure 1. Simulation results: coverage probabilities and expected widths of the 95% credible intervals of 𝜇. Varying 2 for 0.01, 0.02, 0.03,…, 0.20 under fixed n (=7, 15). 
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e-Figure 2. Simulation results: coverage probabilities and expected widths of the 95% credible intervals of 𝜇. Varying n for 4, 5, 6,…, 20 under fixed 2 (=0.1, 0.2). 
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e-Appendix B: Credible intervals for the real data analyses in Section 5 
In Section 5, we provide supplementary analysis results for eight real data examples 
(Crocker et al., 2018; Gaertner et al., 2017; Hauser et al., 2009; Hupfl, Selig and Nagele, 
2010; Riley, Higgins and Deeks, 2011; Sadeghirad et al., 2017; Salvo et al., 2016; Sievert 
et al., 2019); the 95% credible intervals obtained from the 11 priors are presented in e-
Figures 3 and 4. As a reference method, we also present the 95% DL confidence interval 
of 𝜇 (DerSimonian and Laird, 1986). For descriptions of the eight datasets, please see 
Table 1 in Section 5. 
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e-Figure 3. The 95% credible intervals of the grand mean parameter: (a) CPR data (n = 3), (b) corticosteroids data (n = 5), (c) QOL data (n = 7), and (d) PPI data (n = 8). 
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e-Figure 4. The 95% credible intervals of the grand mean parameter: (e) SBP data (n = 10), (f) DPP-4 data (n = 10), (g) breakfast data (n = 10), and (h) pain data (n = 22).
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